🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Knight Therapeutics Inc (GUD)

Toronto
Currency in CAD
5.36
+0.03(+0.56%)
Closed
GUD Scorecard
Full Analysis
Management has been aggressively buying back shares
Fair Value
Day's Range
5.325.39
52 wk Range
5.076.23
Key Statistics
Edit
Bid/Ask
5.29 / 5.36
Prev. Close
5.36
Open
5.35
Day's Range
5.32-5.39
52 wk Range
5.07-6.23
Volume
43.78K
Average Volume (3m)
114.88K
1-Year Change
2.29%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GUD Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
7.09
Upside
+32.28%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet
Show more

Knight Therapeutics Inc Company Profile

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

Employees
725
Market
Canada

Compare GUD to Peers and Sector

Metrics to compare
GUD
Peers
Sector
Relationship
P/E Ratio
−17.6x−1.3x−0.6x
PEG Ratio
0.050.000.00
Price/Book
0.7x0.1x2.6x
Price / LTM Sales
1.5x0.5x3.2x
Upside (Analyst Target)
30.6%47.1%46.2%
Fair Value Upside
Unlock13.3%7.0%Unlock

Analysts' Recommendations

6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7.09

(+32.20% Upside)

People Also Watch

7.78
FEC
+1.57%
13.60
WDO
+2.56%
2.09
CRDL
+0.48%

FAQ

What Is the Knight Therapeutics Inc (GUD) Stock Price Today?

The Knight Therapeutics Inc stock price today is 5.36

What Stock Exchange Does Knight Therapeutics Inc Trade On?

Knight Therapeutics Inc is listed and trades on the Toronto stock exchange.

What Is the Stock Symbol for Knight Therapeutics Inc?

The stock symbol for Knight Therapeutics Inc is "GUD."

What Is the Knight Therapeutics Inc Market Cap?

As of today, Knight Therapeutics Inc market cap is 537.28M.

What is Knight Therapeutics Inc Earnings Per Share?

The Knight Therapeutics Inc EPS is -0.302.

What Is the Next Knight Therapeutics Inc Earnings Date?

Knight Therapeutics Inc will release its next earnings report on Mar 20, 2025.

From a Technical Analysis Perspective, Is GUD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.